On June 11, BeOne Medicines fell 4.17% in regular trading, trading at 158.3 HKD/share, with trading volume of approximately 82.57 million HKD. The stock has been under sustained selling pressure from multiple fronts.

On the news front, Baker Bros. Advisors LP, a key affiliated fund with board representation, recently reduced its holdings by approximately USD 190 million. While the fund still retains a board seat and holds approximately 8.21% of shares, the scale of the reduction has continued to weigh on market sentiment. Additionally, multiple directors have recently made minor reductions in their holdings, further intensifying selling expectations. Southbound capital has net sold on 17 out of the past 20 trading days, with cumulative net reduction exceeding 10.41 million shares.

The broader innovative drug sector has been in correction for over eight months since last September, with the sector benchmark index declining more than 30% over that period. Within the Biotechnology sector today, AKESO fell 2.44%, 3SBIO fell 2.61%, REMEGEN fell 1.86%, and INNOVENT BIO fell 0.47%, reflecting broad-based weakness that continues to drag on BeOne Medicines as a sector heavyweight.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)